Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSCA-CAR T Cells +/- Radiation in mCRPC
NCT05805371Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2024
- Primary completion
- Nov 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PSCA CAR T cells in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 15 years and 50% prostate specific antigen level reduction up to 1 year. Started Oct 2024; status: recruiting.
02
Drugs
PSCA CAR T cells
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05805371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805371.